# Test E2E V15 - RÃ©sumÃ© ExÃ©cutif

**Date**: 2026-02-03 | **Client**: lai_weekly_v15 | **Canonical**: v2.2 | **DurÃ©e**: 1h30

---

## âœ… VERDICT: SUCCÃˆS AVEC RÃ‰SERVES (67%)

**Pipeline E2E fonctionnel et reproductible** - RÃ©sultats identiques Ã  V14

---

## ğŸ“Š RÃ‰SULTATS CLÃ‰S

| MÃ©trique | V13 (Avant) | V15 (AprÃ¨s) | Ã‰volution |
|----------|-------------|-------------|-----------|
| Items ingÃ©rÃ©s | 29 | 29 | = |
| Items relevant | 14 (48%) | 12 (41%) | -14% |
| Score moyen | 38.3 | 81.7 | **+113%** âœ… |
| Faux positifs | 5 | 1 | **-80%** âœ… |
| Faux nÃ©gatifs | 1 | 1 | = |

---

## âœ… SUCCÃˆS (4/6 objectifs)

1. âœ… **Exclusion corporate_move** - MedinCell RH rejetÃ© (score 0)
2. âœ… **Exclusion financial_results** - 3 rapports financiers rejetÃ©s (rule_5)
3. âœ… **DÃ©tection dosing_intervals** - once-weekly, once-monthly, monthly dÃ©tectÃ©s
4. âœ… **Scores cohÃ©rents** - 65-90 pour items relevant, bonne diffÃ©renciation

---

## âŒ PROBLÃˆMES (3 critiques)

1. âŒ **RÃ©gression companies** - 0 companies dÃ©tectÃ©es (vs V13 qui dÃ©tectait)
   - Impact: Perte boost pure_player (+25 points)
   - Affecte: 5-7 items (Nanexa, MedinCell, Camurus)

2. âŒ **Faux nÃ©gatif Quince** - "once-monthly" dans titre NON dÃ©tectÃ©
   - Item rejetÃ© alors qu'il devrait matcher

3. âš ï¸ **Faux positif Eli Lilly** - Manufacturing facility matchÃ© (score 65)
   - "injectables and devices" dÃ©tectÃ© comme signal LAI

---

## ğŸ¯ TOP 5 ITEMS RELEVANT

1. **Teva/MedinCell NDA** (90) - Trademarks + once-monthly + hybrid
2. **UZEDYÂ® Growth** (90) - Trademark + hybrid + dosing
3. **AstraZeneca Saphnelo** (85) - Self-injectable pen + subcutaneous
4. **Camurus Oclaizâ„¢** (85) - Trademark + regulatory
5. **Pfizer GLP-1** (85) - Monthly injectable + technology

---

## ğŸ”§ ACTIONS PRIORITAIRES (V16)

### Critique (Avant V16)

1. **Restaurer dÃ©tection companies** - Modifier generic_normalization.yaml
2. **RÃ©soudre faux nÃ©gatif Quince** - AmÃ©liorer extraction dosing_intervals
3. **Exclure Eli Lilly manufacturing** - Ajouter "injectables and devices" aux exclusions

### Impact attendu V16

- Companies dÃ©tectÃ©es: 0 â†’ 5-7 âœ…
- Items relevant: 12 â†’ 13-14 âœ…
- Faux positifs: 1 â†’ 0 âœ…

---

## ğŸ“ˆ Ã‰VOLUTION V13 â†’ V14 â†’ V15

| Aspect | V13 | V14 | V15 | Tendance |
|--------|-----|-----|-----|----------|
| QualitÃ© scores | âš ï¸ | âœ… | âœ… | ğŸ“ˆ |
| Faux positifs | âŒ 5 | âœ… 0 | âš ï¸ 1 | ğŸ“ˆ |
| Companies | âœ… | âŒ | âŒ | ğŸ“‰ |
| Dosing intervals | âŒ | âœ… | âœ… | ğŸ“ˆ |
| Exclusions | âš ï¸ | âœ… | âœ… | ğŸ“ˆ |

**Conclusion**: Canonical v2.2 stable (V14 = V15) mais nÃ©cessite corrections

---

## ğŸ“ LIVRABLES

- âœ… `items_ingested.json` - 29 items (26 KB)
- âœ… `items_normalized.json` - 29 items (92 KB)
- âœ… `items_analysis.md` - Analyse dÃ©taillÃ©e 12 items relevant
- âœ… `test_e2e_v15_rapport_ingestion_normalisation_scoring.md` - Rapport complet

---

**Recommandation**: ProcÃ©der Ã  V16 avec corrections prioritÃ© 1 (2-3h)
